Watch SNOA. Know when insiders buy.
One email the day a filing lands. Free.
SNOA
Sonoma Pharmaceuticals, Inc.
1.27
+0.02 +1.60%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
76
PASS · shorts 76
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $6.1MP/E —DIV YIELD —FCF YIELD -43.66%REV TTM $21.9M +47.0%NET INCOME −$2.3MNET CASH $5M52W 1.01 – 4.40SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jun 30 | $6.4M | +59.6% | 40.2% | −$40K | −$330K | — | -0.09 | −$649K | $2K | −$651K | Aug 6 |
| Q4 2026 · Mar 31derived | $5.6M | +48.1% | 39.2% | −$351K | −$581K | — | -0.33 | −$519K | $29K | −$548K | Jun 16 |
| Q3 2026 · Dec 31 | $4.3M | +22.0% | 37.9% | −$678K | −$819K | — | -0.48 | −$764K | $47K | −$811K | Feb 10 |
| Q2 2026 · Sep 30 | $5.6M | +56.6% | 37.8% | −$337K | −$534K | — | -0.32 | −$635K | $10K | −$645K | Feb 10 |
| Q1 2026 · Jun 30 | $4M | +18.4% | 36.5% | −$1.1M | −$1.2M | — | -0.76 | −$2M | $106K | −$2.1M | Aug 6 |
| Q4 2025 · Mar 31derived | $3.8M | +9.2% | 40.7% | −$656K | −$776K | — | -0.39 | −$95K | $47K | −$142K | Jun 16 |
| Q3 2025 · Dec 31 | $3.6M | +13.6% | 35.6% | −$1M | −$928K | — | -0.63 | $565K | $2K | $563K | Feb 10 |
| Q2 2025 · Sep 30 | $3.6M | +31.1% | 38.0% | −$850K | −$610K | — | -0.59 | $354K | $26K | $328K | Feb 10 |
| Q1 2025 · Jun 30 | $3.4M | — | 38.5% | −$1.2M | −$1.1M | — | -1.34 | −$912K | $5K | −$917K | Feb 10 |
| Q4 2024 · Mar 31derived | $3.4M | — | 31.7% | −$1.4M | −$1.1M | — | 0.11 | $152K | −$18K | $170K | Jun 17 |
| Q3 2024 · Dec 31 | $3.1M | — | 46.5% | −$844K | −$866K | — | -1.59 | −$1.1M | $1K | −$1.1M | Feb 5 |
| Q2 2024 · Sep 30 | $2.7M | — | 36.3% | −$1.2M | −$1.5M | — | -5.75 | −$1.2M | $2K | −$1.2M | Feb 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Mar 31 | $19.5M | 38.0% | −$2.5M | −$3.2M | -16.3% | -1.89 | −$3.9M | $192K | −$4.1M | — | — |
| FY2025 · to Mar 31 | $14.3M | 38.2% | −$3.7M | −$3.5M | -24.2% | -2.79 | −$88K | $80K | −$168K | — | — |
| FY2024 · to Mar 31 | $12.7M | 37.3% | −$4.7M | −$4.8M | -38.0% | -10.63 | −$2.4M | $2K | −$2.4M | — | — |
| FY2023 · to Mar 31 | $13.3M | 33.7% | −$4.6M | −$5.2M | -38.8% | -1.52 | −$6.2M | $269K | −$6.4M | — | — |
| FY2022 · to Mar 31 | $12.6M | 31.6% | −$5.9M | −$5.1M | -40.3% | -1.92 | −$4.2M | $137K | −$4.4M | — | — |
| FY2021 · to Mar 31 | $18.6M | 35.2% | −$3.4M | −$4M | -21.2% | -1.97 | −$3.4M | $179K | −$3.6M | — | — |
Every number comes from Sonoma Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.